Q-omics provides the consensus-scored DTWD2 profile across patient tissues and cancer cell-line models. DTWD2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DTWD2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, DTWD2 RNA expression shows 19,754 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where DTWD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DTWD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DTWD2 survival associations across molecular data types. DTWD2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DTWD2 RNA expression–survival associations across cancer types. High DTWD2 expression shows unfavorable associations in OV, THCA and HNSC, but favorable associations in KIRC, BRCA and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DTWD2 RNA expression.
This table summarizes DTWD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DTWD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DTWD2 shows lower tumor expression in THCA, KICH, KIRC, COAD and LUSC and higher tumor expression in BRCA. The THCA box plot shows higher DTWD2 RNA expression in normal versus tumor tissue (log2 FC = −1.238, t-test p < 0.001).
This table shows molecular features associated with DTWD2 in patient tissues and cancer cell lines. In patient samples, DTWD2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DTWD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
